Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).-MedSci.cn

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Gao, X; Burris, HA; Vuky, J; Dreicer, R; Sartor, AO; Sternberg, CN; Percent, IJ; Hussain, MHA; Kalebasty, AR; Shen, J; Heath, EI; Abesada-Terk, G; Gandhi, SG; McKean, M; Lu, HL; Berghorn, E; Gedrich, R; Chirnomas, SD; Vogelzang, NJ; Petrylak, DP

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (6):

科室
- - 订阅+
  - 更多科室
工具
服务